Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Achieves First Milestone In Parke-Davis Deal; Sets Up US R&D Site

Premium

TEL AVIV--Compugen announced recently that it had met the first milestone in its Leads platform agreement with Parke-Davis ahead of schedule, which activated an undisclosed milestone payment from Parke-Davis, a division of Warner-Lambert.

Leads is a computational biology platform for the modeling and understanding of molecular mechanisms of life. Late last year Parke-Davis became the first of a planned total of three major pharmaceutical company partners for the Leads platform, under a multiyear, multimillion-dollars-per-year agreement.

"The Leads platform is already proving to be a significant factor in furthering our genomic research efforts," said Wendell Wierenga, Parke-Davis senior vice-president of preclinical research, development, and technologies.

As part of its Leads effort, Compugen has just opened a US R&D and partner support center in Jamesburg, NJ. Led by Simchon Faigler, cofounder and vice-president of technology, the new facility will house a multidisciplinary team of research and application scientists focusing on further development of the Leads Platform.

The initial focus for the development of Leads was the extraction of meaningful information, such as new genes, proteins, and splice variants, from expressed and genomic data. Current development efforts include improved chip design and pattern recognition from chip and proteomics expression results.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.